

May 26, 2017

To: Cancer Clinical Researchers and Staff

RE: Cancer Protocol Review Committee (CPRC) Policy Updates

CPRC Merger

Beginning March 7, 2017 the TI and NTI CPRC subcommittees merged into one CPRC. One committee will strengthen our reviews and enhance the function of the CPRC as our method to ensure scientific integrity of all interventional trials done at the Masonic Cancer Center per the NCI guidelines for comprehensive cancer centers.

Benefits of one committee include:

- Higher attendance, which will enhance the quality of discussion during meetings.
- Decreased turnaround time for NT studies since they will now be reviewed twice per month.
- A more complete and thorough review of studies that border the line between treatment and non-treatment.

An updated committee meeting dates and deadlines schedule has been posted on the website:
<https://www.cancer.umn.edu/for-researchers/investigator-resources/cancer-protocol-review-committee>

Increased Annual Accrual Minimum

Beginning March 1, 2017, the CPRC increased the minimum annual accrual requirement from 30% to 50% of the projected goal. This was done at the recommendation of the NCI upon interim review of the CPRC in 2016.

All continuing reviews going forward will be held to the 50% accrual requirement. Any studies accruing less than 50% of their annual accrual goal will be asked to provide detailed justification for the low accrual.

Sincerely,



Brenda Weigel, MD
Co-Chair, Cancer Protocol Review Committee



Mark Kirstein, PharmD
Co-Chair, Cancer Protocol Review Committee